The newly formed single brand becomes one of the largest information systems providers for laboratories globally across healthcare, life sciences, and public health, the company suggested.
In total, Clinisys has a portfolio of over 3,000 customers, in eight industries and 22 science disciplines, spread across 34 countries. The company offers laboratory information management solutions to its clients.
When asked about what services Clinisys offers specifically to the pharma industry, the company’s CEO, Michael Simpson, told Outsourcing-Pharma, “Clinisys’ solutions provide end-to-end support for labs operating at every stage of the drug discovery lifecycle. This continues into production quality testing and then into monitoring efficacy long-term, through our disease surveillance and case management platforms.”
In addition to these services, Clinisys also offers integrated solutions in document management and electronic notebooks.
In terms of the informatics challenges facing those working in labs, Simpson outlined that the greatest requirement is to develop efficient processes.
“There is a revolution occurring in laboratory sciences diagnostics as it plays a more real-time role in preventative and precision medicine – from detecting the spread of infectious diseases, to supporting genomics and drug discovery. All these exciting developments mean there is a massive surge in diagnostic testing and the volume of data that laboratories must manage,” said Simpson.
Clinisys helps labs to overcome these challenges by providing efficient workflows and with a greater degree of accuracy, through the use of automation and data visualization tools. The company also enables labs to shift their data into the cloud and is looking ahead to the future of advanced data analytics, which will include machine learning.
By combing the three companies, Clinisys will now cover laboratory sectors within the healthcare, water, crop sciences, contract services, life sciences, environmental, food & beverage, pharma, and public health industries.
When asked about the advantage of covering such a broad range of industries, Simpson stated, “This enables us to connect critical data provided from diverse laboratory sources while retaining our commitment to providing best-of-breed solutions.
“We have built on our capabilities in healthcare to improve clinical outcomes, as well as the life sciences – in fields such as pharma, biotech molecular, and genomics. All these disciplines will become ever-more important to understand all the factors that shape the health and wellbeing of our communities, as we move to more of a preventative approach to managing health.”